Bio-Techne Corp
Gesloten
SectorGezondheidszorg
56.32 1
Overzicht
Wijziging aandelenprijs
24u
Min
55.68
Max
57.13
Inkomsten | 13M 51M |
|---|---|
Verkoop | 16M 311M |
K/W Sectorgemiddelde | 80.243 49.712 |
EPS | 0.53 |
Dividendrendement | 0.59 |
Winstmarge | 16.392 |
Werknemers | 3,100 |
EBITDA | 21M 99M |
Aanbevelingen | Buy |
|---|---|
12 Maanden Prognose | +7.7% upside |
Dividendrendement Sectorgemiddelde | 0.59% 2.36% |
|---|---|
Volgende Winsten | 5 aug 2026 |
Volgende dividenddatum | 28 aug 2026 |
Marktkapitalisatie | 230M 8.8B |
|---|---|
Vorige openingsprijs | 55.32 |
Vorige sluitingsprijs | 56.32 |
Nieuwssentiment
By Acuity
76%
24%
303 / 342 Rangschikking in Healthcare
Bio-Techne Corp Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Over Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.